Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00119
|
|||||
| Drug Name |
Arsenic trioxide
|
|||||
| Synonyms |
Acide arsenieux [French]; Anhydride arsenieux [French]; Arseni trioxydum; Arsenic blanc [French]; Arsenic oxide (As2O3); Arsenic trioxide (JP15/USAN); Arsenic trioxide [JAN]; Arsenic trioxide [UN1561] [Poison]; Arsenic(3+); Arsenic(III) trioxide; Arsenigen saure [German]; Arsenious Acid Anhydride; Arsenious trioxide; Arsenous oxide [ISO]; Arsenox; Arsentrioxide; Naonobin; Oxyde Arsenieux; Oxyde Arsenieux [ISO-French]; Oxygen(2-); Trisenox; Trisenox (TN); Trixenox
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Acute lymphoblastic leukemia [ICD11: 2B33.0] | Approved | [1] | |||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
As2O3
|
|||||
| Canonical SMILES |
[O-2].[O-2].[O-2].[As+3].[As+3]
|
|||||
| InChI |
InChI=1S/2As.3O/q2*+3;3*-2
|
|||||
| InChIKey |
QTLQKAJBUDWPIB-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 1327-53-3
|
|||||
| Pharmaceutical Properties | Molecular Weight | 197.841 | Topological Polar Surface Area | 3 | ||
| Heavy Atom Count | 5 | Rotatable Bond Count | 0 | |||
| Hydrogen Bond Donor Count | 0 | Hydrogen Bond Acceptor Count | 3 | |||
| PubChem CID | ||||||
| PubChem SID | ||||||
| ChEBI ID |
ChEBI:30621
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Arsenic trioxide was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | MRP2 and acquired tolerance to inorganic arsenic in the kidney of killifish (Fundulus heteroclitus). Toxicol Sci. 2007 May;97(1):103-10. | |||||
| 3 | Arsenic trioxide induces apoptosis equally in T lymphoblastoid leukemia MOLT-4 cells and P-gp-expressing daunorubicin-resistant MOLT-4 cells. Cancer Chemother Pharmacol. 2003 Feb;51(2):119-26. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.